Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.52 |
| ▸ | CASP7 | P55210 | 14/20 | 0.52 |
| ▸ | CASP1 | P29466 | 6/20 | 0.52 |
| ▸ | CASP9 | P55211 | 5/20 | 0.52 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.43 |
| ▸ | CASP4 | P49662 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | CASP5 | P51878 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1396481 | 0.90 | CASP3 (0.47) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL1396588 | 0.87 | CASP3 (0.49) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL1396586 | 0.82 | CASP3 (0.47) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL1396589 | 0.80 | CASP3 (0.59) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL1396580 | 0.79 | CASP3 (0.52) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL1396434 | 0.78 | CASP3 (0.51) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL9929920 | 0.77 | CASP3 (0.48) | CASP3CASP7CASP1CASP9CTSL | |
| SCHEMBL3718444 | 0.76 | CASP3 (0.50) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL3718219 | 0.75 | CASP3 (0.48) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL3719261 | 0.72 | CASP3 (0.50) | CASP3CASP7CASP1CASP9CASP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
| EP-2288615-B1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-06-21 | — | — | EP | disclosed |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
| US-9562069-B2 | Selective caspase inhibitors and uses thereof | NEW WORLD LABORATORIES INC. (CA) | 2017-02-07 | — | — | US | disclosed |
| US-9045524-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2015-06-02 | — | — | US | disclosed |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8791235-B2 | Selective caspase inhibitors and uses thereof | NOVAGENESIS FOUNDATION (CH) | 2014-07-29 | — | — | US | disclosed |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES, INC. (CA) | 2012-06-21 | — | — | US | disclosed |
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2011-03-31 | — | — | US | disclosed |
| EP-2288615-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | New World Laboratories Inc. (CA) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010133000-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
| WO-2009140765-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | NEW WORLD LABORATORIES INC. (CA) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077190-A1 | Selective Caspase Inhibitors and Uses Thereof | CASP3, CASP1, HTRA2 | CASP3 1/4885CASP7 9/4885CASP1 2/4885 |
| US-20150011458-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP3, CASP1, HTRA2 | CASP3 1/4885CASP7 9/4885CASP1 2/4885 |
| US-20120157394-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, VIP, CASP5 | CASP3 6/4885CASP7 13/4885CASP1 1/4885 |
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.